Syndax Pharmaceuticals Inc header image

Syndax Pharmaceuticals Inc

SNDX

Equity

ISIN null / Valor 24112479

NASDAQ (2026-02-26)
USD 20.67-0.39%

Syndax Pharmaceuticals Inc
UMushroom community rating:

star star star star star
4.26 18 votes No rating yet
NegativeNeutralPositive

About company

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company aims to extend and improve the lives of cancer patients by leveraging cutting-edge scientific research and advancements. Syndax collaborates with various stakeholders in the medical and scientific communities to identify and develop promising drug candidates. The company's pipeline includes treatments designed to address unmet medical needs in oncology, with a particular emphasis on novel mechanisms of action and overlooked aspects of cancer biology. Through these efforts, Syndax seeks to bring new, effective treatment options to market, enhancing patient outcomes and advancing the field of cancer therapy.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

32.8%1Y
-13.8%3Y
-15.3%5Y

Performance

68.9%1Y
57.0%3Y
58.9%5Y

Volatility

Market cap

1797 M

Market cap (USD)

Daily traded volume (Shares)

1,358,587

Daily traded volume (Shares)

1 day high/low

12.75 / 12.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.26

18 votes
Performance:
starstarstarstarstar
3.92
Innovation:
starstarstarstarstar
4.32
Society:
starstarstarstarstar
4.43
Nature:
starstarstarstarstar
4.15
Liam Hawkeswood
Switzerland, 18 Nov 2025
star star star star star
Liam Hawkeswood
Switzerland, 11 Nov 2025
star star star star star
****** Panggabean
United Kingdom, 09 Nov 2025
star star star star star
High risk and volatile performance. However, it has high upside potential and people are anticipating future returns

EQUITIES OF THE SAME SECTOR

QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.70%USD 22.70
iRhythm Technologies Inc
iRhythm Technologies Inc iRhythm Technologies Inc Valor: 34117792
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.15%USD 140.18
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.31%CHF 128.10
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.47%CAD 25.72
Johnson & Johnson
Johnson & Johnson Johnson & Johnson Valor: 943981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.69%USD 243.47
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 461641
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.42%USD 37.62
Merck & Co Inc
Merck & Co Inc Merck & Co Inc Valor: 10683053
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.58%USD 119.30
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.04%USD 27.10
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.31%USD 116.26
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.52%SEK 288.50